| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/BJS.9761 |
| P698 | PubMed publication ID | 25624168 |
| P50 | author | Giles J. Toogood | Q47319809 |
| P2093 | author name string | K R Prasad | |
| A J Sutton | |||
| J P A Lodge | |||
| K J Roberts | |||
| P2860 | cites work | Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial | Q24647888 |
| What defines 'cure' after liver resection for colorectal metastases? Results after 10 years of follow-up. | Q33865014 | ||
| Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases | Q33874670 | ||
| Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial | Q33922925 | ||
| Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis | Q34318787 | ||
| Trends in long-term survival following liver resection for hepatic colorectal metastases | Q34523502 | ||
| Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial | Q34656647 | ||
| Actual 10-year survival after resection of colorectal liver metastases defines cure. | Q34699863 | ||
| Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer | Q34711514 | ||
| First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study | Q35705210 | ||
| Systemic therapy for colorectal cancer | Q36029007 | ||
| Open versus laparoscopic left lateral hepatic sectionectomy within an enhanced recovery ERAS® programme (ORANGE II-trial): study protocol for a randomised controlled trial. | Q36130128 | ||
| Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. | Q36889705 | ||
| Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials | Q37269696 | ||
| Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. | Q39275325 | ||
| Hepatic resection for metastatic colorectal cancer results in cure for some patients | Q41479460 | ||
| Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan. | Q42651373 | ||
| Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus be | Q48310135 | ||
| Impact of the UK colorectal cancer screening pilot studies on incidence, stage distribution and mortality trends. | Q51568508 | ||
| Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. | Q52599881 | ||
| The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. | Q52693985 | ||
| Effect of specialist decision-making on treatment strategies for colorectal liver metastases. | Q53103788 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 388-398 | |
| P577 | publication date | 2015-01-26 | |
| P1433 | published in | British Journal of Surgery | Q4970212 |
| P1476 | title | Cost-utility analysis of operative versus non-operative treatment for colorectal liver metastases. | |
| P478 | volume | 102 |
| Q33753364 | Perforation of the cecum resulting from a closed-loop obstruction in a patient with an adenocarcinoma of the sigmoid colon: a case report. |
| Q33605471 | The use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review. |
Search more.